 RTT News | A Walk Through Rigel Pharma RTT News R548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune disorders. The compound is currently under phase I studies. The company's preclinical programs include,. * R348, a soluble JAK/SYK inhibitor for Sjogren's syndrome, ... |
